Corcept Shares Jump as Korlym Wins First Cushing's Approval
Shares of Corcept Therapeutics Inc. jumped nearly 50 percent aftermarket on Friday as news began to spread that the Menlo Park, Calif.-based biotech had won FDA approval of Korlym (mifepristone) to treat hyperglycemia in patients with Cushing's syndrome.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST